tirzepatide osa approval FDA Approves First Sleep Apnea Drug Clinical Capsules: Zepbound for Zzz's:

Friis-Moller N, Sabin CA, Weber R, et al

MASH is considered progressive

Head-to-head clinical evidence SURPASS-2: Mounjaro vs Ozempic in type 2 diabetes The SURPASS-2 trial, published in the New England Journal of Medicine, directly compared tirzepatide with semaglutide 1 mg (the standard Ozempic dose) in 1,879 people with type 2 diabetes over 40 weeks

This finding is in contrast with the expectation from Mendelian randomization analyses, showing an association between genetically predicted lower C3 levels and depression risk

What to Expect: Timeline of Results Understanding the typical progression of benefits helps set realistic expectations and maintain motivation through the early stages of treatment